Migraine preventive therapy: Selection of appropriate patients and general principles of management

Expert Review of Neurotherapeutics

Volumn 6, Issue 8, 2006, Pages 1147-1157

  D'Amico, Domenico ^a   Lanteri Minet, Michel ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b PASTEUR HOSPITAL   (France)

Author keywords

Headache; Migraine; Prevention; Prophylaxis

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; ERGOTAMINE; FLUNARIZINE; FROVATRIPTAN; MAGNESIUM; MONOAMINE OXIDASE INHIBITOR; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PIZOTIFEN; PROPRANOLOL DERIVATIVE; RIBOFLAVIN; RIZATRIPTAN; SUMATRIPTAN; TOPIRAMATE; TRIPTAN DERIVATIVE; VALPROATE SEMISODIUM; VALPROIC ACID; VERAPAMIL;

BRADYCARDIA; CLINICAL TRIAL; DIAGNOSTIC ERROR; DISABILITY; DISEASE DURATION; DISEASE SEVERITY; HEADACHE; HUMAN; HYPERTENSION; MENSTRUATION; MIGRAINE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK REDUCTION; TANACETUM PARTHENIUM;

ADRENERGIC BETA-ANTAGONISTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CALCIUM CHANNEL BLOCKERS; HUMANS; MIGRAINE DISORDERS; PATIENT COMPLIANCE; PATIENT SELECTION;

EID: 33747192872     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.8.1147     Document Type: Review

References (86)

1. Lipton RB, Diamond M, Freitag FG, Bigal M, Stewart WF, Reed ML. Migraine prevention patterns in a community sample: results from the American Migraine Prevalence and Prevention (AMPP) Study, Poster F38. Headache 45, 792 (2005).
2. Lucas C, Chaffaut C, Artaz MA, Lanteri-Minet M. FRAMIG-2000: medical and therapeutic management of migraine in France. Cephalalgia 25(4), 267-280 (2005).
3. Kors EE, Vanmolkot KR, Haan J, Frants RR, van den Maagdenberg AM, Ferrari MD. Recent findings in headache genetics. Curr. Opin. Neurol. 17, 283-288 (2004).
4. Bowyer SM, Aurora SK, Moran JE, Tepley N, Welch KMA. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann. Neurol. 50, 582-587 (2001). • The work conducted by Welch's team was the first to clearly support the hypothesis that migraine is caused by brain hyperexcitability, which becomes a significant target for migraine prevention.
5. Wray SH, Mijovic-Prelec D, Kosslyn SM. Visual processing in migraineurs. Brain 118, 25-35 (1995).
6. Leao AAP. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 7, 379-390 (1944).
7. Freitag FG. Divalproex in the treatment of migraine. Psychopharmacol. Bull. 37(Suppl. 2), 98-115 (2003).
8. Welch KMA. Brain hyperexcitabiliy: the basis for antiepileptic drugs in migraine prevention. Headache 45(Suppl. 1), S25-S32 (2005).
9. 1B/D agonists: insights in migraine pathophysiology using rizatriptan. Neurology 55(9 Suppl. 2), S8-S14 (2000).
10. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol. 55, 19-26 (2004). • The central sensitization development during a migraine attack results in the re-examination of the acute treatment strategy in migraine patients. Such an approach will probably be applied in the future to address preventive treatment choices.
11. Weiller C, May A, Limmroth V et al. Brain stem activation in spontaneous human migraine attacks. Nat. Med. 1, 658-660 (1995).
12. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 41, 941-943 (2001).
13. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41, 646-657 (2001). • A complete review of migraine in terms of high prevalence, high morbidity, and consequent substantial impact both on individual patients and on society as a whole and of frequent misdiagnosis of this condition.
14. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 23, 519-527 (2003).
15. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd Edition. Cephalalgia 24(Suppl. 1), 1-160 (2004).
16. Lanteri-Minet M, Valade D, Geraud G, Chautard MH, Lucas C. Migraine and probable migraine: results of FRAMIG 3, a French nationwide survey carried out according to the 2004 IHS classification. Cephalalgia 25(12), 1146-1158 (2005). • This nationwide, population-based survey performed in France using the 2004 International Headache Society (IHS) classification shows that both strict and probable migraine, which have similar prevalence and impact on migraine subjects, deserve similar medical and therapeutic management.
17. Stewart WF, Sheder AL, Simon D, Liberman JN. Migraine prevalence. A review of population-based studies. Neurology 44(Suppl. 4), S17-S23 (1994).
18. Abu-Arehf I, Russell G. Prevalence of headache and migraine in schoolchildren. Br. Med. J. 309, 765-969 (1994).
19. Bille B. Migraine in school children: prevalence, clinical features, and a 30-year follow-up. In: Migraine and Other Headaches. Ferrari MD, Lataste X (Eds). Parthenon, NJ, USA (1989).
20. D'Amico D, Usai S, Grazzi L, Solari A, Curone M, Bussone G. The impact of primary headaches on patients lives: Italian experience with the MIDAS and the SF-36 questionnaires. Headache Care 1, 123-128 (2004).
21. Lambert J, Carides GW, Meloche JP, Gerth WC, Marentette MA. Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a Phase III clinical trial. Can. J. Clin. Pharmacol. 9(3), 158-164 (2002).
22. Gerth WC, Carides GW, Dasbach EJ, Visser WH, Santanello NC. The multinational impact of migraine symptoms on healthcare utilization and work loss. Pharmacoeconomics 19, 197-206 (2001). • Direct and indirect costs of migraine are significant determinants to justify the preventive treatment of the disease to health authorities.
23. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. 10, 255-259 (1999).
24. Dahlöf CHG, Dimenäis E. Migraine patients experience: poor subjective wellbeing/quality of life even between attacks. Cephalalgia 15, 31 (1995). • The demonstration of the quality-of-life decrease between the attacks is essential to understand the need for preventive treatment in patients with migraine.
25. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology 55(Suppl. 2), S29-S36 (2000).
26. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology 55(5), 629-635 (2003).
27. Dueland AN, Leira R, Cabelli ST. The impact of migraine on psychological well-being of young women and their communication with physicians about migraine: a multinational study. Curr. Med. Res. Opin. 21, 1297-1305 (2005).
28. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache 34, 337-343 (1994).
29. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population: the GEM study. Neurology 55, 624-629 (2000).
30. Linde M, Dahlof C. Attitudes and burden of disease among self-considered migraineurs - a nation-wide population-based survey in Sweden. Cephalalgia 24, 455-465 (2004).
31. Holmes WF, MacGregor EA, Sawyer JP, Lipton RB. Information about migraine disability influences physicians perceptions of illness severity and treatment needs. Headache 341, 343-350 (2001).
32. Stewart WF, Lipton RB, Whyte J et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53, 988-994 (1999).
33. Kosinski M, Bayliss MS, Bjorner JB et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual. Life Res. 12(8), 963-974 (2003).
34. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 58, 885-894 (2002).
35. Brandes JL. Global trends in migraine care: results from the MAZE survey. CNS Drugs 16(Suppl. 1), 13-18 (2002).
36. Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ. Why headache treatment fails. Neurology 60, 1064-1070 (2003).
37. Gibbs TS, Fleischer AB Jr, Feldman SR, Sam MC, O'Donovan CA. Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache 43, 330-335 (2003).
38. Vuillaume de Diego E, Lantéri-Minet M. Recognition and management of migraine in primary care: influence of functional impact measured by headache impact test (HIT). Cephalalgia 25, 184-190 (2005). •• The burden of migraine management is directly related to inadequate evaluation of the functional impact by general practitioners.
39. Taylor F, Hutchinson S, Graff-Radford S, Cady R, Harris L. Diagnosis and management of migraine in family practice. J. Fam. Pract. (Suppl.), S3-S24 (2004).
40. Landy S. Migraine throughout the life cycle: treatment through the ages. Neurology 62(Suppl. 2), S2-S8 (2004).
41. Pryse-Phillips WE, Dodick DW, Edmeads JG et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ 156, 1273-1287 (1997).
42. Hu XH, O'Donnell F, Kunkel RS, Gerard G, Markson LE, Burger ML. Survey of migraineurs referred to headache specialist: care, satisfaction, and outcomes. Neurology 55, 141-143 (2000).
43. Geraud G, Lanteri-Minet M, Lucas C, Valade D, French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin. Ther. 26, 1305-1318 (2004).
44. Dowson AJ, Lipscombe S, Sender J, Rees T, Watson D, MIPCA Migraine Guideline Development Group. Migraine in Primary Care Advisors. New guidelines for the management of migraine in primary care. Curr. Med. Res. Opin. 18, 414-439 (2002).
45. Lipton RB, Dodick D, Sadovsky R et al. A self-administered screener for migraine in primary care. Neurology 61, 375-382 (2000).
46. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality of life: a population-based case-control study from England. Cephalalgia 23, 441-450 (2003).
47. Tepper SJ, D'Amico D, Boas V, Dowson AJ. Guidelines for prescribing prophylactic medications for migraine: a survey among headache specialist physicians in different countries. Headache Care 1, 267-272 (2004).
48. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology 54, 1553 (2000).
49. Silberstein SD, Lipton RB. Chronic daily headache including transformed migraine, chronic tension-type headache, and medication overuse. In: Wolff 's Headache and Other Head Pain. 7th Edition. Silberstein SD, Lipton RB, Dalessio DJ (Eds). Oxford University Press, NY, USA, 247-282 (2001).
50. Katsarava Z, Schneeweiss S, Kurth T et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62(5), 788-790 (2004).
51. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106, 81-89 (2003). •• Chronic daily headache is the main complication of migraine. Determining the risk factors for this complication is essential when evaluating the appropriateness of migraine prevention.
52. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache 41, 573-578 (2001).
53. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache 43, 336-342 (2003).
54. D'Amico D, Grazzi L, Usai S, Rigamonti A, Curone M, Bussone G. Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache 45(5), 553-560 (2005).
55. Powers C, Szeto S, Pangtay D, Bort T, Cervi M, Cady R. Evaluation of migraineurs preferences for naratriptan over conventional first-line agents. Arch. Fam. Med. 9(8), 753-758 (2000).
56. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 39(Suppl. 2), S20-S26 (1999).
57. Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, Lopez-Gil A. START 10 Study Group. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. Clin. Ther. 25(7), 2053-2069 (2003).
58. MacGregor EA, Brandes J, Eikermann A, Giammarco R. Impact of migraine on patients and their families: the Migraine and Zolmitriptan Evaluation (MAZE) survey - Phase III. Curr. Med. Res. Opin. 20, 1143-1150 (2004).
59. Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: a review. Curr. Pain Headache Rep. 7, 55-62 (2003).
60. Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 44(Suppl. 1), S20-S30 (2004).
61. Rahman A, Segasothy M, Samad SA, Zulfiqar A, Rani M. Analgesic use and chronic renal disease in patients with headache. Headache 33, 442-445 (1993).
62. D'Amico D, Solari A, Usai S et al., for the Lombardy Headache Project Group. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. a prospective longitudinal multicenter study. Cephalalgia 26(6), 691-696 (2006). •• Clear demonstration of how prevention can reduce the burden of migraine, both in terms of direct consequences of attacks (reduction of disability during migraine episodes) and of quality of life between attacks (improvement in sense of well being and functioning in different roles).
63. Ware JE. SF-36 health survey update. Spine 25, 3130-3139 (2000).
64. Diamond M, Dahlof C, Papadopoulos G, Neto W, Wu SC. Topiramate improves health-related quality of life when used to prevent migraine. Headache 45(8), 1023-1030 (2005).
65. Silberstein SD, McCrory DC. Migraine preventive medication reduces resource utilization. Headache 43, 171-178 (2003). •• First study to evaluate the benefits for society, deriving from preventive therapy of migraine in terms of resource utilization.
66. Evans RW, Bigal ME, Grosberg B, Lipton RB. Target doses and titration schedules for migraine preventive medications. Headache 46(1), 160-164 (2006).
67. Palevitch D, Earon G, Carusso R. Feverfew (tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother. Res. 11, 508-511 (1997).
68. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 16(4), 257-263 (1996).
69. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50(2), 466-470 (1998).
70. Allais G, Bussone G, De Lorenzo C, Mana O, Benedetto C. Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects. Neurol. Sci. 26(Suppl. 2), S125-S129 (2005).
71. Mannix LK, Files JA. The use of triptans in the management of menstrual migraine. CNS Drugs 19(11), 951-972 (2005).
72. Aube M. Improving patient compliance to prophylactic migraine therapy. Can. J. Neurol. Sci. 29(Suppl. 2), S40-S43 (2002).
73. Ferrari A, Sternieri E, Ferraris E, Bertolini A. Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis. Pharmacol. Res. 48, 1-9 (2003).
74. Topiramate (Topamax). Physicians' Desk Reference. Medical Economics Co, Inc, Montvale, NJ, USA, 2541-2548 (2005).
75. Divalproex (Depakote ER). Physicians' Desk Reference. Medical Economics Co, Inc, Montvale, NJ, USA, 441-447 (2005).
76. Propranolol (Inderal LA). Physicians' Desk Reference. Medical Economics Co, Inc, Montvale, NJ, USA, 3336-3337 (2005).
77. Verapamil hydrochloride. Physicians' Desk Reference. Medical Economics Co, Inc, Montvale, NJ, USA, 479-481 (2005).
78. Mulleners WM, Whitmarsh TE, Steiner TJ. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia 1, 52-56 (1998).
79. Massiou H. Migraine medication attributes are important for patient compliance. Drugs Today 39(Suppl. D), 25-29 (2003).
80. Dodick D. Patient perceptions and treatment preferences in migraine management. CNS Drugs 16(Suppl. 1), 19-24 (2002).
81. MacGregor EA. The doctor and the migraine patient: improving compliance. Neurology 48(Suppl. 3), S16-S20 (1997).
82. D'Amico D. Treatment strategies in migraine patients. Neurol. Sci. 25, S242-S243 (2004).
83. Turner A. Development of a complete diary and checklist for headache patients. Headache Care 1(3), 199-206 (2004).
84. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. Neurology [serial online]. www.neurology.org. (Accessed 15 September 2004). •• As in other medical fields, evidence-based pharmacologic data are essential to define the best preventive strategy in the management of migraine.
85. Migraine sufferers keep working despite their pain. Market Wire. April 21, 2003. www.marketwire.com/mw/release_html_b1?release_id=53037. (Accessed 18 October 2004).
86. Therapie der Migräneattacke und Migranëprophylaxe. www.dmkg.de/thera/konse.htm. (Accessed 13 January 2005).